A detailed history of Tang Capital Management LLC transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Tang Capital Management LLC holds 7,811,760 shares of CTMX stock, worth $7.81 Million. This represents 0.79% of its overall portfolio holdings.

Number of Shares
7,811,760
Previous 7,791,936 0.25%
Holding current value
$7.81 Million
Previous $9.51 Million 3.04%
% of portfolio
0.79%
Previous 1.16%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.12 - $1.51 $22,202 - $29,934
19,824 Added 0.25%
7,811,760 $9.22 Million
Q2 2024

Aug 14, 2024

BUY
$1.21 - $5.13 $1.62 Million - $6.88 Million
1,341,936 Added 20.81%
7,791,936 $9.51 Million
Q1 2024

May 15, 2024

SELL
$1.41 - $2.74 $141,000 - $274,000
-100,000 Reduced 1.53%
6,450,000 $14.1 Million
Q4 2023

Feb 14, 2024

SELL
$1.07 - $1.55 $53,500 - $77,500
-50,000 Reduced 0.76%
6,550,000 $10.2 Million
Q2 2023

Aug 14, 2023

BUY
$1.41 - $1.92 $714,824 - $973,378
506,968 Added 8.32%
6,600,000 $11.4 Million
Q1 2023

May 15, 2023

BUY
$1.48 - $2.88 $3.82 Million - $7.44 Million
2,582,587 Added 73.57%
6,093,032 $9.2 Million
Q4 2022

Feb 14, 2023

BUY
$1.19 - $1.91 $2.92 Million - $4.69 Million
2,455,772 Added 232.85%
3,510,445 $5.62 Million
Q2 2022

Aug 15, 2022

BUY
$1.53 - $2.89 $1.61 Million - $3.05 Million
1,054,673 New
1,054,673 $1.93 Million
Q1 2022

May 16, 2022

SELL
$2.67 - $4.68 $406,761 - $712,974
-152,345 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$3.87 - $7.39 $589,575 - $1.13 Million
152,345 New
152,345 $660,000
Q4 2020

Feb 16, 2021

SELL
$6.47 - $7.9 $730,333 - $891,752
-112,880 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$6.55 - $8.83 $1.23 Million - $1.65 Million
-187,120 Reduced 62.37%
112,880 $751,000
Q1 2020

May 15, 2020

BUY
$3.61 - $8.6 $1.08 Million - $2.58 Million
300,000 New
300,000 $2.3 Million

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $66M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Tang Capital Management LLC Portfolio

Follow Tang Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tang Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tang Capital Management LLC with notifications on news.